BTZ and CFZ were previously tested as single agents, or in combination with platinum or other chemotherapeutic agents, in multiple phase I/II NSCLC clinical trials (12, 34) with a modest efficacy signal observed in a few of the combination trials (with docetaxel, gemcitabine, or carboplatin), mostly in relapsed/refractory disease (35, 36). The gene discussed is CASC3; the disease is non-small cell lung carcinoma.